Equities

Research Alliance II Corp

RACB:NAQ

Research Alliance II Corp

Actions
  • Price (USD)9.85
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 14 2021 20:59 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Research Alliance Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It has not selected any specific business combination target and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company intend to focus on the healthcare industry, with an emphasis on the biotechnology sector. The Company neither engages in any business operations nor generates any revenues.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2020
  • Employees--
  • Location
    Research Alliance II Corp3172 North Rainbow Blvd., #1278LAS VEGAS 89108United StatesUSA
  • Phone+1 (617) 778-2500
  • Fax+1 (302) 655-5049
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Special Opportunities Fund Inc.-100.00bn-100.00bn186.54m--------------------------------------------------------------
AMCI Acquisition Corp II-100.00bn-100.00bn186.75m----7,970.63----------0.0012----------------------------0.8306--------------
Colombier Acquisition Corp-100.00bn-100.00bn186.95m----1.37----------7.04----------------------------0.0004--------------
Alpha Healthcare Acquisition Corp III-100.00bn-100.00bn187.52m----10,764.89----------0.0009----------------------------0.7654--------------
ABG Acquisition I Corp-100.00bn-100.00bn187.53m----1.28----------7.57----------------------------0.00--------------
Oxus Acquisition Corp-100.00bn-100.00bn187.64m----29,643.36----------0.0003----------------------------0.9779--------------
ARYA Sciences Acquisition Corp V-100.00bn-100.00bn188.03m----19,804.40----------0.0005----------------------------0.9463--------------
Coliseum Acquisition Corp-100.00bn-100.00bn188.49m----1.35----------7.20----------------------------0.00--------------
Research Alliance II Corp-100.00bn-100.00bn188.99m----1.30----------7.59----------------------------0.00--------------
Goldman Sachs MLP and Energy Renassnc Fd-421.37k76.24m189.58m--2.510.881----4.634.63-0.025213.21-0.0025------45.81-8.0247.69-8.14---582.24---1,774.60----0.0659---82.93-49.07-154.16-----23.64
Altimar Acquisition Corp III-100.00bn-100.00bn189.79m----1.36----------7.20----------------------------0.00--------------
Tortoise Midstream Energy Fund Inc1.51m64.12m190.62m--2.980.924--126.2611.3511.350.274236.560.0057--1.34--24.32-9.0626.12-9.11-76.95-116.634,247.04-1,947.28----0.2583---42.67-10.66-249.96-----16.44
Dividend And Income Fund Inc-100.00bn-100.00bn190.69m--------------------------------------------------------------
ARYA Sciences Acquisition IV Corp-100.00bn-100.00bn190.91m----1.31----------7.58----------------------------0.00--------------
VolitionRX Ltd58.01k-21.11m191.32m65.00--7.16--3,298.10-0.4221-0.42210.00120.50300.0019--6.09892.46-68.94-85.39-82.31-100.35-----36,540.11-265,907.20---147.930.1296---21.46---26.42--71.14--
Nuveen Intermediate Duration Qlty Mun FD8.55m13.94m192.00m--13.780.9802--22.451.061.060.65314.960.0344--2.08--5.603.045.623.0977.0071.31162.9488.57----0.21976.975.59-1.40145.00-2.13---4.53
Data as of Oct 14 2021. Currency figures normalised to Research Alliance II Corp's reporting currency: US Dollar USD

Institutional shareholders

52.48%Per cent of shares held by top holders
HolderShares% Held
HealthCor Management LPas of 30 Jun 20211.32m8.58%
Perceptive Advisors LLCas of 30 Jun 20211.00m6.47%
Citadel Advisors LLCas of 30 Jun 2021926.07k5.99%
Laurion Capital Management LPas of 30 Jun 2021800.00k5.18%
Alyeska Investment Group LPas of 30 Jun 2021800.00k5.18%
Farallon Capital Management LLCas of 30 Jun 2021750.00k4.86%
Woodline Partners LPas of 30 Jun 2021750.00k4.86%
RTW Investments LPas of 30 Jun 2021637.00k4.12%
Sphera Funds Management Ltd.as of 30 Jun 2021600.00k3.88%
Pura Vida Investments LLCas of 30 Jun 2021520.18k3.37%
More ▼
Data from 30 Jun 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.